ERBB2 and breast carcinoma: Although the impact of HER2 misclassification on clinical outcomes is unclear, 20 – 30 % of patients with HER2-positive advanced breast cancer do not respond to first-line treatment combinations, despite advances in anti-HER2 therapies [10].